MiNK Therapeutics, Inc. (INKT)
2025-06-30 | ||||
|---|---|---|---|---|
| Foreign currency translation loss | -56,877 | |||
| Other income (expense), net | -185,703 | |||
| Research and development | 1,839,176 | |||
| General and administrative | 1,849,130 | |||
| Change in fair value of related party note | 364,090 | |||
| Operating loss | -4,052,396 | |||
| Interest income, net | 348 | |||
| Net loss | -4,237,751 | |||
| Comprehensive loss | -4,294,628 | |||
| Earnings per share, basic | -1.06 | |||
| Earnings per share, diluted, total | -1.06 | |||
| Weighted average number of shares outstanding, basic | 3,981,992 | |||
| Weighted average number of shares outstanding, diluted, total | 3,981,992 | |||